{"id":"NCT01351480","sponsor":"Arthritis & Rheumatic Disease Specialties Research","briefTitle":"Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients","officialTitle":"Assessment of Structural Benefits of Injectable Abatacept as Measured by MRI in RA Patients Who Have Failed Prior Anti-Tumor Necrosis (TNF) Therapy and Correlated With Clinical Outcomes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2014-01","completion":"2014-04","firstPosted":"2011-05-11","resultsPosted":"2017-03-13","lastUpdate":"2017-03-13"},"enrollment":34,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"abatacept","otherNames":["orencia"]}],"arms":[{"label":"abatacept","type":"OTHER"}],"summary":"The purpose of this study is to determine if the use of sub-cutaneous (SC) abatacept provides any structural benefit in patients with rheumatoid arthritis who have failed prior use of TNF therapy.","primaryOutcome":{"measure":"Number of Participants With an Improvement in Bone Edema/Osteitis on Low-field MRI in Rheumatoid Arthritis Patients on Weekly SC Abatacept in Combination With Methotrexate Over a 12-month Period.","timeFrame":"MRIs at Baseline and Week 48","effectByArm":[{"arm":"Abatacept","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":18},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":[]}}